Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Study Summary

A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to include an additional 120 adult participants in a cohort called GRAND CANYON, that is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of sevasemten in adults with Becker. CANYON and GRAND CANYON are fully enrolled.

Conditions

Becker Muscular Dystrophy

Interventions / Drugs

Sevasemten 10 mg Sevasemten 5 mg Sevasemten 12.5 mg Placebo

View on ClinicalTrials.gov ↗

Sponsor

EWTX

Edgewise Therapeutics

Cardiomyopathy

D38/100

Study Details

Enrollment244 participants

Primary Completion—

Lead SponsorEdgewise Therapeutics, Inc.

Data Retrieved2026-04-11 04:13:37.458666+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.